Endometrial Serous Adenocarcinoma — Trials

Endometrial Serous Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

51 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 15
Recruiting: 7
Ph III recruiting: 2
Growth YoY: —
Industry share: 20%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–15 of 15 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04719273	Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer	completed	Phase 2	14	Thomas Jefferson UniversityOTHER	1	Jul 17, 2026	clinicaltrials
NCT04814108	A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma	completed	Phase 2	92	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY	4	Mar 18, 2026